Biomaterials, Journal Year: 2024, Volume and Issue: 316, P. 123020 - 123020
Published: Dec. 15, 2024
Language: Английский
ACS Nano, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 20, 2025
Cytokine therapeutics in cancer immunotherapy are greatly limited by their short half-time, serious toxicity, and frequent administration, which can possibly be addressed ribonucleic acid (RNA) technology through the expression of targeting cytokines situ. However, intracellular translation RNA remains restricted due to generation excessive reactive oxygen species (ROS) overconsumption adenosine triphosphate (ATP) within transfected cells. Herein, hybrid lipid nanoparticles (Mn-LNPs) developed incorporating small-sized trimanganese tetraoxide conventional nanoparticles, showing ability generate oxygen, eliminate ROS, boost ATP, thus enhancing efficiency. This platform is employed encapsulate interleukin 12 (IL-12)-encoding circular (Mn-LNPs@RNAIL-12) for tumor immunotherapy, exhibiting unparalleled advantages proliferation cytotoxic T cells stimulation antitumor immunity. Moreover, efficacy Mn-LNPs@RNAIL-12 further strengthened synergizing with immune checkpoint blockade therapy achieve durable potent performances.
Language: Английский
Citations
1
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 14, 2025
Abstract Implant‐associated infections (IAIs) are refractory to elimination, and the local immunosuppressive microenvironment (IME) exacerbates therapeutic difficulties, ultimately causing persistence relapse. Therefore, exploring immunostrengthening treatments holds great promise for reversing IME thoroughly eradicating chronic or repetitive infections. Bacterial outer membrane vesicles (OMVs) have emerged as potential immunostimulatory candidates; however, they lack active targeting capabilities cause non‐specific inflammatory side effects. In this study, bone marrow‐derived mesenchymal stem cells (BMSCs) genetically engineered overexpress CXCR4 isolated cell membranes (mBMSC ) hybridization with OMVs derived from Escherichia coli ( E. produce nanovesicles @OMV). The resulting mBMSC @OMV demonstrate excellent marrow capability effectively taken up by macrophages, triggering efficient transition pro‐inflammatory M1 status through TLR/NF‐κB pathway. This alteration promotes innate bactericidal capacity antigen presentation. Subsequent activation of T B inhibition myeloid‐derived suppressor (MDSCs) facilitated in vivo adaptive immunity mouse models. Additionally, boosted memory bacteria‐specific antibody responses. Together, these data highlight eradicate complicated IAIs provide whole‐stage protection against postsurgical relapse, thus marking a significant immunotherapeutic advancement post‐antibiotic era.
Language: Английский
Citations
0
Interdisciplinary cancer research, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0
Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 535, P. 216641 - 216641
Published: March 30, 2025
Language: Английский
Citations
0
Essays in Biochemistry, Journal Year: 2025, Volume and Issue: 69(02)
Published: March 28, 2025
The emergence of immunotherapy has led to the clinical approval several related drugs. However, their efficacy against solid tumors remains limited. As hub immune activation, lymph nodes (LNs) play a critical role in tumor by initiating and amplifying responses. Nevertheless, intricate physiological structure barriers within LNs, combined with immunosuppressive microenvironment induced cells, significantly impede therapeutic immunotherapy. Engineered nanoparticles (NPs) have shown great potential overcoming these challenges facilitating targeted drug transport LNs directly or indirectly activating T cells. This review systematically examines structural features key factors influencing targeting efficiency NPs, current strategies for remodeling LNs. Additionally, it discusses future opportunities optimizing NPs enhance immunotherapy, addressing translation safety evaluation.
Language: Английский
Citations
0
Published: Jan. 1, 2025
Language: Английский
Citations
0
Colloids and Surfaces B Biointerfaces, Journal Year: 2024, Volume and Issue: 245, P. 114321 - 114321
Published: Oct. 15, 2024
Language: Английский
Citations
2
Advanced Science, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 24, 2024
Melanoma, a malignant skin tumor, presents significant treatment challenges, particularly in unresectable and metastatic cases. While immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have brought new hope, their efficacy is limited by low response rates immune-mediated adverse events (irAEs). Through multi-omics data analysis, it discovered that the spatial co-localization of CD73 PD-L1 melanoma correlates with improved progression-free survival (PFS), suggesting synergistic potential inhibitors. Building on these insights, novel therapeutic strategy using calcium phosphate (CaP) nanoparticles developed for co-delivery aPD-L1 APCP, inhibitor. These nanoparticles, constructed via biomineralization method, exhibit high drug-loading capacity pH-responsive drug release. Compared to free aPD-L1, CaP-delivered effectively avoids systemic side effects while significantly enhancing anti-tumor efficacy, surpassing even 20-fold dose aPD-L1. Furthermore, APCP CaP demonstrates effect, substantial activation prevention tumor recurrence through memory effects. findings suggest promising approach improving immunotherapy, achieving enhanced reduced toxicity.
Language: Английский
Citations
2
Chemical Society Reviews, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 2, 2024
We discuss the recent advances in nanomaterial design strategies for immunometabolic modulatory platforms and their applications targeting cancer-immunity cycle to enhance therapeutic outcomes.
Language: Английский
Citations
1